Features | Partner Sites | Information | LinkXpress
Sign In

Agreement to Expand Distribution for MR Volumetric Brain Atrophy Software

By Medimaging International staff writers
Posted on 10 Feb 2014
New software is the only US Food and Drug Administration (FDA)-approved medical device capable of automatically detecting and quantifying atrophy in the human brain and provides accurate, and fully automated magnetic resonance imaging (MRI) post-processing capabilities to the physician’s mobile device or desktop.

This provides radiologists, neuroadiologists, and clinical researchers with a convenient and cost-effective way to quantify atrophy of brain structures to help identify a range of brain disorders, including conditions such as Alzheimer’s disease, epilepsy and traumatic brain injury.

CorTechs Labs (La Jolla, CA, USA) reported that it is renewing and expanding a partnership and distribution agreement with Invivo Corp. (Gainesville, FL, USA;  a subsidiary of Philips Healthcare [Best, The Netherlands]) for NeuroQuant, a software solution for volumetric brain atrophy in the US healthcare market.

NeuroQuant is a crucial part of Invivo’s DynaSuite neuroimaging solution. “We’re pleased to expand our relationship with Invivo. With great expertise and presence in advanced clinical solutions for MRI, Invivo has been a terrific partner and has demonstrated exceptional growth with our NeuroQuant product in the US,” said Guri Stark, CorTechs Labs’ CEO. “We look forward to partnering with Invivo to continue NeuroQuant’s growth momentum and establishing our vision to have NeuroQuant become the standard test for all brain disorders, including Alzheimer’s disease, epilepsy and traumatic brain injury.”

“CorTechs Labs is a pioneer in the area of software for the aid of brain diagnostics and has a tremendous track record of reliability and automation in clinical practices,” stated Tom Tynes, director of strategic business development at Invivo. “We look forward to continuing to offer our DynaSuite neuroimaging solution with NeuroQuant, benefitting from its innovative approach to providing the much needed quantitative brain volumetric information.”

CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ cornerstone product, NeuroQuant, is a breakthrough, 510(k)-cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.

Invivo is a subsidiary of Philips Healthcare (Best, The Netherlands) and develops progressive MRI coils, cutting-edge clinical solutions, and MRI-compatible interventional devices.

Related Links:

CorTechs Labs

SuperSonic Imagine



view channel

Leading Cancer Center Among First in Europe to Treat Patients Using Robotic Patient-Positioning Radiotherapy Couch

A Viennese hospital has become one of the first oncology departments in Europe to introduce clinical treatments using a robotic radiotherapy patient-positioning couch. Kaiser-Franz-Josef Hospital (KFJ; Vienna, Austria) has introduced this enhanced patient positioning device, which enables more flexibility during radiotherapy... Read more


view channel
Image: The Accent MRI pacemaker and Tendril MRI lead (Photo courtesy of St. Jude Medical).

US Patent Allows Full-Body MRI Technology for Use with Pacemakers

A California hospital is first in the United States to conduct magnetic resonance imaging (MRI) of a patient implanted with a new MRI-compatible pacemaker. Cardiothoracic surgeon Raymond Schaerf, MD... Read more


view channel
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).

Hepatocellular Carcinoma Screening Linked with Curative Treatment and Longer Survival in Cirrhosis Patients

Investigators discovered that patients with cirrhosis who underwent surveillance (using liver ultrasound with or without measurement of serum alpha fetoprotein) for hepatocellular carcinoma (HCC) had cancers... Read more

Nuclear medicine

view channel
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography). Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.